| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
Form 4: Landry John, Chief Financial Officer
Received 41,433 shares as a grant or award · Granted 186,447 Stock Option (right to buy) |
| 12 Nov 2026 |
Form 3: Landry John, Chief Financial Officer
No securities owned |
| 05 Nov 2026 | FORM S-8 |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
MINNEAPOLIS, November 5, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients wi... |
| 02 Oct 2026 | SCHEDULE 13D/A |
| 21 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On behalf of CVRx, Inc. (“CVRx” or the “Company”), I am pleased to offer you employment with CVRx. Subject to fulfillment of the conditions of employment mentioned in this letter, your estimated hire date will be October 12, 2026, pendin... |
| 24 Aug 2026 | SCHEDULE 13D |
| 14 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 |
Form 4: Binkowski Brent, CHIEF OPERATING OFFICER
Bought 26,223 shares ($76.4K) |
| 13 Aug 2026 |
Form 4: Binkowski Brent, CHIEF OPERATING OFFICER
Sold 1,309 shares ($3.34K) |
| 11 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
MINNEAPOLIS, August 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients wit... |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
MINNEAPOLIS, August 6, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... |
| 09 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
I want to thank you for your service to CVRx, Inc. (the “Company”). I understand you have chosen to transition from CVRx and appreciate your willingness to effect a smooth transition as outlined in this letter agreement (“Agreement”). |
| 03 Jun 2026 |
Form 4: Nielsen Kirk G., Director
Received 8,720 shares as a grant or award · Granted 11,182 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: Jain Mudit K., Director
Received 8,720 shares as a grant or award · Granted 11,182 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: Slattery Joseph P, Director
Received 8,720 shares as a grant or award · Granted 11,182 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: Hill, Mitch C., Director
Received 8,720 shares as a grant or award · Granted 11,182 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: Ballinger Kevin J., Director
Received 8,720 shares as a grant or award · Granted 11,182 Stock Option (right to buy) |
Loading...